High 5s Project
|This article needs additional citations for verification. (May 2011) (Learn how and when to remove this template message)|
The High 5s name derives from the Project’s original intent to significantly reduce the frequency of 5 challenging patient safety problems in 5 countries over 5 years.
The countries that initiated the High 5s Project were Australia, Canada, Germany, the Netherlands, New Zealand, the United Kingdom, and the United States. France, Saudi Arabia, and Singapore have subsequently joined the Project. All the countries set up Lead Technical Agencies for coordination of national project activities.
The project is supported by the U.S. Agency for Healthcare Research and Quality, WHO, and the Commonwealth Fund and is coordinated by the WHO Collaborating Centre for Patient Safety which is led by The Joint Commission and Joint Commission International.
The Mission of the High 5s Project is to facilitate implementation and evaluation of standardized patient safety solutions within a global learning community to achieve measurable, significant and sustainable reductions in challenging patient safety problems.
The major components of the High 5s Project include the development and implementation of problem-specific Standardized Operating Protocols (SOPs); creation of an Impact Evaluation Strategy; collection of data, reporting and analysis; and the establishment of an electronic collaborative learning community.
The High 5s Project is designed to generate learning that will permit the continuous refinement and improvement of the SOPs, as well as assessment of the feasibility and success of implementing standardized approaches to specific patient safety problems across multiple countries and cultures. Achievement of the Project goals is expected to provide valuable lessons and new knowledge to support the advancement of patient safety around the world.
Five SOPs have been developed to support the Project. These SOPs address:
- 1.Assuring Medication Accuracy at Transitions in Care
- 2.Managing Concentrated Injectable Medicines
- 3.Performance of Correct Procedure at Correct Body Site
- 4.Communication failures during patient handovers
- 5.Addressing health care-associated infection.
Each SOP summarizes the problem, the strength of evidence that supports the solution, potential barriers to adoption, potential unintended consequences created by the solution, patient and family roles in the solution, and references and resources.
The Impact Evaluation Strategy includes on-site observation of SOP implementation; the use of SOP-specific performance measures; use of an event analysis framework to identify occurrences that may represent SOP failures: and baseline and periodic hospital safety culture surveys.
- German Agency for Quality in Medicine
- German Coalition for Patient Safety
- National Patient Safety Agency
- Patient safety
- World Health Organization
- WHO Collaborating Centre on Patient Safety
- Joint Commission International
- The Joint Commission
- Agency for Healthcare Research and Quality
Lead Technical Agencies
- Australia: Australian Commission on Safety and Quality in Health Care
- Canada: Canadian Patient Safety Institute
- France: French National Authority for Health
- Germany: German Agency for Quality in Medicine & German Coalition for Patient Safety
- The Netherlands: Dutch Institute for Healthcare Improvement - CBO
- Singapore: Ministry of Health, Singapore
- United Kingdom: National Patient Safety Agency
- United States: Agency for Healthcare Research and Quality & American College of Surgeons
- Fact Sheet: High 5s Project Overview
- Press Release
- SOP for Implementation: Assuring medication accuracy at transitions in care
- SOP for Implementation: Managing concentrated injectable medicines
- SOP for Implementation: Performance of correct procedure at correct body site